Investigational drug · Phase 2
BAY3018250
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Thrombolysis, Symptomatic Proximal Deep Vein Thrombosis.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "BAY3018250"
First trial start
2024
Jan 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BAY3018250", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thrombolysis
- Symptomatic Proximal Deep Vein Thrombosis
Approved drugs for the same conditions: Blood clots (DVT and pulmonary embolism) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BAY3018250" as an intervention, largest first.
- A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein ThrombosisPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT06149520 · 283 participants · Start Jan 15, 2024 · Primary completion Oct 7, 2025
Drug: BAY3018250; Placebo to BAY3018250 · For: Thrombolysis; Symptomatic Proximal Deep Vein Thrombosis
Sites: Antwerp, Belgium; Bonheiden, Belgium; Genk, Belgium · 68 sites in all
BayerBayer (BAYRY)
NCT06562985 · 39 participants · Start Sep 18, 2024 · Primary completion Jan 6, 2025
Drug: BAY3018250 Dose 1; Placebo and 3 more · For: Acute Venous and Arterial Thrombotic and Thromboembolic Events; Healthy Volunteers
Sites: Los Alamitos, California
BayerBayer (BAYRY)
NCT06619483 · 24 participants · Start Oct 10, 2024 · Primary completion Jan 24, 2025
Drug: BAY3018250 Dose 1; Placebo and 1 more · For: Acute Venous and Arterial Thrombotic and Thromboembolic Events; Healthy Volunteers
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Antibody BAY3018250 against antiplasmin enhances plasminogen activation in vitro and thrombolysis in rabbits.
Lindo CJ, Liao P, Khan A, et al. · J Thromb Haemost 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bayer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.